A compounding pharmacy that leaves Form 483 observations uncorrected does not simply wait out the silence. FDA escalates the matter to an FDA warning letter, a public enforcement document that names the facility, cites the specific provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act) at issue, and starts a new response clock. For a 503A pharmacy or a 503B outsourcing facility already compounding semaglutide or tirzepatide under heightened FDA scrutiny, the warning letter is the last point where a documented, complete response can still close the file without a consent decree, an injunction, or a referral to the state board of pharmacy and the DEA.
When Unresolved Observations Become A Warning Letter
FDA issues a warning letter when inspection findings, often the same observations first recorded on a Form 483, amount to violations of regulatory significance that were not promptly and adequately corrected. FDA's own guidance on Form 483 responses states that an ongoing or promised corrective action does not, by itself, prevent a warning letter from issuing; the agency looks for correction that has actually been completed and verified. A 483 response that lists intended fixes without documented completion carries real escalation risk. The warning letter restates the violations in terms of the specific FD&C Act provisions and regulations implicated, and functions as FDA's public notice that continued inaction will draw further enforcement.
The 15 Working Day Response Window
A warning letter's closing paragraph gives the recipient 15 business days from receipt to respond in writing with the specific steps taken to correct each violation, an explanation of the steps taken to prevent recurrence, and copies of supporting documentation. A facility that cannot complete corrective action within that window must state the reason for the delay and the date by which correction will be complete. This deadline runs separately from, and after, the 15 business day window FDA recommends for the initial Form 483 response. Missing it, or filing a response that restates intentions instead of documenting completed action, exposes the facility to further action, including seizure, injunction, or criminal referral, without additional notice.
A warning letter response that promises correction without proving it happened is the version FDA is least likely to close out.
What FDA Credits As An Adequate Response
FDA's review of a warning letter response asks whether the facility identified the root cause of each violation, determined whether the failure was isolated or systemic, and built a corrective action plan with defined timelines rather than aspirational language. The applicable framework, addressed in 503A vs 503B: Which Framework Governs Your Compounding, shapes which USP and current good manufacturing practice requirements the letter cites. A response that treats a systemic failure as an isolated event, or promises correction without proof it occurred, is the pattern most likely to draw a follow-up inspection rather than a close-out letter.
Reinspection And The Close-Out Letter
FDA does not close out a warning letter on the strength of representations that correction will happen or has happened. The agency's standard method for verifying correction is a follow-up inspection, and FDA issues a close-out letter only when the written response, the reinspection, or other information demonstrates that the cited violations were adequately corrected and no other significant violations turned up. A facility that is not reinspection-ready, meaning its corrective action plan is not yet fully implemented and documented when FDA returns, risks a second inspection that produces new or repeat observations. For a compounding pharmacy, that outcome compounds quickly. FDA findings tied to a warning letter are commonly shared with the state board of pharmacy and, when controlled substances are involved, the DEA, carrying licensure and registration exposure well beyond the original FDA matter.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies and outsourcing facilities promptly retain healthcare defense counsel upon receiving an FDA warning letter. Early legal intervention can protect the facility's rights, ensure the written response is accurate, complete, and appropriately documented, avoid inadvertent admissions that surface later in enforcement, preserve relevant defenses, and allow counsel to communicate with the FDA district office and the Office of Compounding Quality and Compliance on the facility's behalf. Delaying legal representation until after a response has already been drafted, or until the 15 business day window has closed, can significantly affect the outcome of the matter and expose the facility to unnecessary regulatory and enforcement risk.
How Health Law Alliance Can Help
Health Law Alliance represents compounding pharmacies and outsourcing facilities through the warning letter response process, from assessing whether the observations cited at the 483 stage were adequately addressed, through drafting the corrective action response, coordinating root cause investigations with quality and regulatory staff, and preparing the facility for the reinspection that determines whether FDA issues a close-out letter. If your pharmacy or facility has received an FDA warning letter, contact us for a free, confidential consultation.
